Potential application areas: Lung cancer, breast cancer, colon cancer, pancreatic cancer, prostate cancer, leukemia, melanoma, etc.
Decades of investigation has revealed how a progressive series of mutations can cause disruptions of normal cell functions, eventually resulting in malignant tumors. As the disease advances, the levels of protein biomarkers in the blood fluctuate in response to both the cancer progression and response to treatment. Hundreds of biomarkers have been implicated in the biology of cancer and Myriad RBM has assembled the largest available collection of quantitative immunoassays to identify cancer-related biomarker patterns for various aspects of oncology research.
Click or mouse over biomarkers for more information